生物制药公司Cytokinetics宣布,其创新药物Myqorzo®(Aficamten)已获得欧盟委员会正式批准,适用于治疗成人症状性梗阻性肥厚型心肌病(HCM)。这一监管里程碑标志着该药物在欧洲市场取得重要进展,为患有此类心脏疾病的患者提供了新的治疗选择。
生物制药公司Cytokinetics宣布,其创新药物Myqorzo®(Aficamten)已获得欧盟委员会正式批准,适用于治疗成人症状性梗阻性肥厚型心肌病(HCM)。这一监管里程碑标志着该药物在欧洲市场取得重要进展,为患有此类心脏疾病的患者提供了新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.